Bob Leibenluft is a partner in the Washington D. C. office of Hogan Lovells LLP. His practice is devoted entirely to counseling, investigations and litigation regarding antitrust matters in the health care sector, and his clients include health care providers, health plans and drug and device manufacturers. Mr. Leibenluft graduated magna cum laude from Yale University in 1973 and received his J.D. from Boalt Hall School of Law, University of California at Berkeley in 1980 where he elected to the Order of the Coif. Upon completing law school, Mr. Leibenluft worked as an attorney advisor in the Federal Trade Commission (FTC)'s Office of Policy Planning, concentrating on health and antitrust matters. In 1981, he joined Hogan & Hartson (which has since become Hogan Lovells) and became a partner in the firm in 1989. He practiced health law at Hogan & Hartson until January 1996 when he rejoined the FTC as Assistant Director for Health Care in the FTCs Bureau of Competition. As head of the Health Care Division, Mr. Leibenluft supervised a 25-30 person staff engaged in the review of mergers, acquisitions, and joint ventures involving hospitals, physicians, and other health care providers, as well as conduct in the health care and pharmaceutical industries. While at the FTC, Mr. Leibenluft supervised the 1996 revisions of the FTC and DOJ Statements of Antitrust Enforcement Policy in Health Care which first addressed clinical integration among health care providers. He rejoined Hogan & Hartson in September 1998. Mr. Leibenluft is an Inaugural Fellow of the American Health Lawyers Association. He is a former member of the Board of Directors and Vice-President of AHLA and former Chair of the ABA Antitrust Section Health Care Committee, State Enforcement Committee, and Joint Conduct Committee. He is Chair of the Board of Directors of HCI3, the parent company of Prometheus Payment Inc. and Bridges to Excellence. Bob is also an adjunct law professor at the George Washington University School of Law where he teaches a course on Antitrust in the Health Care Sector.